Jove
Visualize
お問い合わせ

関連する概念動画

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

332
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
332
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

213
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
213
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

71
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
71
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  1. ホーム
  3. 心臓のミオシン結合タンパク質cレベルは,安定した冠動脈疾患の重度と予後に関連しています.
  1. ホーム
  3. 心臓のミオシン結合タンパク質cレベルは,安定した冠動脈疾患の重度と予後に関連しています.

関連する実験動画

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.8K

心臓のミオシン結合タンパク質Cレベルは,安定した冠動脈疾患の重度と予後に関連しています.

Xuechun Shen1, Jingyu Sun2, Qianhang Long3

  • 1Department of Cardiology, Northern Jiangsu People's Hospital, Yangzhou, 225001, Jiangsu, China.

Scientific reports
|August 28, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

心臓のミオシン結合タンパク質-C (cMyBP-C) は,安定した冠動脈疾患 (CAD) の存在と重症性を予測する. cMyBP- C値が上昇すると,1年以内に重大な心血管疾患 (MACE) のリスクが高くなります.

キーワード:
心臓のミオシン結合タンパク質Cゲンシニ・スコア主要な心血管疾患リスクの階層化安定した冠動脈疾患

さらに関連する動画

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K
Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm
06:18

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm

Published on: September 17, 2021

1.5K

関連する実験動画

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.8K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K
Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm
06:18

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm

Published on: September 17, 2021

1.5K

科学分野:

  • 心臓病科
  • バイオマーカーの発見
  • 臨床診断

背景:

  • 心筋ミオシン結合タンパク質-C (cMyBP-C) は,急性冠動脈症候群のバイオマーカーとして認識されています.
  • 安定した冠動脈疾患 (CAD) とその予後的な影響におけるその役割は十分に確立されていません.

研究 の 目的:

  • cMyBP-Cレベルと安定したCADの存在と重度の関連性を評価する.
  • 安定したCAD患者の1年間の主要な心血管疾患 (MACE) の予測値を評価する.

主な方法:

  • 冠動脈血管検査を受けた367人の患者の横断分析.
  • cMyBP- CレベルとCADの重症度に関するゲンシニスコア (GS) の相関
  • 190人の安定したCAD患者を追跡し,加速障害時間 (AFT) モデルを用いて1年間のMACEを追跡した.

主要な成果:

  • c MyBP- Cレベルは,安定したCADの患者では,それ以外の患者と比較して有意に高かった (28. 0 vs 6. 0 pg/ ml,P < 0. 001).
  • cMyBP- Cはゲンシニスコア (r=0. 44,P < 0. 001) と正の相関関係があり,独立してCADの存在と重症性を予測した.
  • 増加したcMyBP- C (≥27 pg/ ml) は,安定したCAD患者のMACEまでの時間 (加速因数0. 66,P=0. 02) と独立して関連していました.

結論:

  • 循環中のcMyBP-Cは,安定したCADの存在と血管学的重度の独立した予測因子です.
  • cMyBP- C値が上昇した患者は,1年間のMACEのリスクが高くなります.
  • cMyBP- Cは,安定したCAD患者における総合的なリスク分層のバイオマーカーとして有望であり,さらなる検証が必要である.